Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADAP
Nasdaq
8731
https://www.adaptimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adaptimmune Therapeutics PLC -
Adaptimmune gets FDA designation to accelerate development of cancer therapy
- Dec 3rd, 2019 7:20 pm
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
- Dec 3rd, 2019 1:30 pm
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT
- Nov 17th, 2019 4:40 pm
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
- Nov 16th, 2019 7:00 am
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
- Nov 6th, 2019 12:30 pm
Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019
- Nov 1st, 2019 12:00 pm
Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds
- Oct 31st, 2019 5:52 pm
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies
- Oct 9th, 2019 12:00 pm
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
- Oct 1st, 2019 12:00 pm
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
- Sep 30th, 2019 12:45 pm
Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market?
- Sep 16th, 2019 10:41 am
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
- Sep 10th, 2019 1:01 pm
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
- Sep 9th, 2019 12:00 pm
Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT
- Aug 27th, 2019 6:11 pm
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
- Aug 27th, 2019 12:00 pm
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
- Aug 16th, 2019 3:23 pm
Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript
- Aug 2nd, 2019 2:24 am
Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
- Aug 1st, 2019 11:15 am
New Executive Team Announced at Adaptimmune
- Aug 1st, 2019 11:15 am
Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
- Jul 29th, 2019 8:05 pm
Scroll